Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA’s Parks Expands REMS Portfolio With Move To ODE II Deputy Slot

This article was originally published in The Pink Sheet Daily

Executive Summary

Currently the head of the Division of Metabolic and Endocrinology Products, Parks has handled drug safety controversies in diabetes and obesity products.


Related Content

Arthritis Patient Classification To Be Key Issue In TNF Inhibitor Reviews
Avandia RECORD Study Re-Analysis To Get FDA Committee Scrutiny
J&J Gains FDA OK For First-In-Class Type 2 Diabetes Drug Invokana
FDA’s Opioid To-Do List Could Redefine Pain Market For Brands, Generics
Use Of Pre-Approval CV Data From Ongoing Trial Gets Once-Over At Canagliflozin Panel
Orexigen Defines A Way To Get The Contrave PDUFA Clock Ticking
Opioid Prescriber Knowledge Assessment Due Year After Patient Assessment
CV Risk Assessment For All Obesity Drugs Seems Inevitable Pre-Approval Requirement
Anatomy Of The Avandia Decision: FDA’s Woodcock Splits The Difference Between OND, OSE Views
FDA’s Diabetes Guidance On CV Risk Will Get First Test With Pending NDAs


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts